Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.
-
Upload
laurence-blair -
Category
Documents
-
view
220 -
download
5
Transcript of Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.
![Page 1: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/1.jpg)
Advocating for Clinical Trial Accrual
Karen Van De Steeg
Executive Director
![Page 2: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/2.jpg)
June E. Nylen Cancer Center
• Joint venture of Mercy and St. Luke’s in 1995
• Free-standing outpatient facility
• Primary offices for medical and radiation oncologists
![Page 3: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/3.jpg)
Mission
• To Provide the highest quality, compassionate care through prevention, treatment and research for the people of Siouxland
![Page 4: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/4.jpg)
Screening Programs
Coming Soon: CT Lung Cancer Screening
![Page 5: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/5.jpg)
Patient Services• Chemotherapy and medical oncology services• Radiation therapy – Trilogy!• PET/CT, CT, X-ray• Dietitian, Patient navigator, Spiritual
coordinator, Massage therapist, Accupuncturist, Wellness clinic, Art therapy, Support groups
• 16 satellite clinics
![Page 6: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/6.jpg)
Research
Mission driven commitment to: Providing the best possible care close to
homeFinding a cure for cancer
![Page 7: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/7.jpg)
Clinical Trials Accrual
at the June E. Nylen Cancer Center and
Siouxland Hematology-Oncology Associates
![Page 8: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/8.jpg)
“Clinical trials are research studies conducted with people who volunteer to take part. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease. People who take part in cancer clinical trials have an opportunity to contribute to knowledge of, and progress against, cancer. They also receive up-to-date care from experts.”
National Cancer Institute - NCI
![Page 9: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/9.jpg)
What influences accrual?
Attitude = Enthusiasm
![Page 10: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/10.jpg)
What influences accrual?
• Physicians and Administration
• Memberships/Associations
• Knowledgeable Staff
• Knowledgeable and Willing Participants
![Page 11: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/11.jpg)
Enthusiasm by Physicians
The Physicians must have:
An inherent belief that clinical trials are a necessary and beneficial component to a cancer center’s patient care system
Administration must have:
The same commitment and financial resources
![Page 12: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/12.jpg)
Physicians and Administration Support the Staff
• Protocol director
• Eleven research coordinators
• Over 70 nurses, technicians, office staff
• Two dosimetrists, two physicists
• Six Radiation therapists
• Support staff
![Page 13: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/13.jpg)
“This is your new work station… um, you’ll have to remove your watch.” -Don Mayne
![Page 14: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/14.jpg)
Protocol Staff
![Page 15: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/15.jpg)
Multiple Memberships
• National Cancer Institute• Community Clinical Oncology Program
• Industry (pharma companies)
![Page 16: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/16.jpg)
Industry Associations
• Amgen
• Genentech
• GSK
• Wyeth
• And others to fill the niche
![Page 17: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/17.jpg)
National Cancer InstituteAssociations
• July 16, 1983 – NCI launched the Community Clinical Oncology Program
– to establish a cancer control effort that combines the expertise of community oncologists with NCI clinical research programs.
![Page 18: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/18.jpg)
National Cancer Institute
Associations
• CCOPs involve thousands of medical professionals
• Mid-1980s Dr. Michalak joins ECOG as a Principal Investigator
• 2003 Dr Wender becomes Medical Director and PI
![Page 19: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/19.jpg)
NCI CCOP
• June E Nylen Cancer Center, Sioux City, IA• Sanford in Sioux Falls, SD
and Fort Collins, CO• St. Luke’s and Mercy
• Pathologists• IRB members
• Sixteen Satellite Clinics• Abben Cancer Center, Spencer, IA
![Page 20: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/20.jpg)
NCI CCOP
• Siouxland Hematology-Oncology Associates
– 6 medical oncologists plus staff
• June E Nylen Cancer Center
– 2 radiation oncologists plus staff
![Page 21: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/21.jpg)
CCOP Memberships
• ECOG – Eastern Cooperative Oncology Group (Boston, MA)
• NCCTG – North Central Cancer Treatment Group (Mayo Rochester, MN)
• NSABP – National Surgical Adjuvant Breast and Bowel Project (Pittsburgh, PA)
• CCCWFU – Comprehensive Cancer Center Wake Forest U (Winston-Salem, NC)
![Page 22: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/22.jpg)
CCOP Memberships
• CTSU – Clinical Trials Support Unit (Rockville, MD)
• SWOG – Southwest Oncology Group (San Antonio, TX)
• CALGB – Cancer and Leukemia Group B (Chicago, IL)
• GOG – Gynecologic Oncology Group (Philadelphia, PA)
![Page 23: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/23.jpg)
Lots of Memberships, Lots of Trials,
Lots of Types of Trials
![Page 24: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/24.jpg)
Lots of Memberships, Lots of Trials,Lots of Types of Trials
• Treatment
• Prevention
• Cancer Control– Symptom Management/Quality of Life
• Ancillary Studies- Studies within Studies• Quality of Life• Lab studies: pharmacokinetics,
pharmacogenetics, EKGs
![Page 25: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/25.jpg)
Selecting Trials
• Sponsors send us protocols to review whether the sponsor is cooperative group or industry.
• PI reviews our ability to accrue based on potential study population, the study scientific integrity, and competing trials
• IRB process completed
![Page 26: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/26.jpg)
Knowledgeable Physicians and Staff
• Receive summaries of all new protocols– Research staff– Nurses– Physicians
• Full copies in work room and on computer for all to view
![Page 27: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/27.jpg)
Knowledgeable Staff• Binders throughout the clinic containing the
Clinical Trial Worksheets arranged by disease site– Contain brief eligibility criteria for each open study
– Reference in which binder to locate the full version
– About 200 binders in the
workroom that need to be
updated each time the
protocol is amended
– Need to make computer access to protocols more convenient
![Page 28: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/28.jpg)
Know the Advantages
• Participants have access to promising new approaches that are often not available outside the clinical trial setting
• Doctors, nurses and staff gain upfront first-hand knowledge of cutting-edge therapies
![Page 29: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/29.jpg)
Know the Advantages
• Regular and careful medical attention from a team that includes doctors and other health professionals
• Frequent monitoring as part of the clinical trial
• Results from the study may help others in the future
![Page 30: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/30.jpg)
Know the Disadvantages
• New drugs or procedures under study may not be better than the standard treatment
• New treatments may have side effects or risks that doctors do not expect
• Participants in randomized trials will not be able to choose the approach they receive
• More visits to the doctor may be required if part of a clinical trial
![Page 31: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/31.jpg)
Knowledgeable Coordinators
• Research CRAs as Coordinators• Educate and train other staff• Coordinate participant activity• Certified as Research Professionals• Industry studies are assigned based on the CRAs
workload, and if they have experience with the study drug and sponsor
• Cooperative group studies are not assigned to individual CRAs
![Page 32: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/32.jpg)
Knowledgeable Coordinators
• Research CRAs as Recruiters• Upfront screening of EVERY patient chart for
potential participants• Actively alert Investigator to available trials• Participate in community outreach projects
![Page 33: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/33.jpg)
![Page 34: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/34.jpg)
Knowledgeable Nurses
• Knowledge of the advantages and disadvantages of clinical trials participation for patients and staff
• Receive summaries of all protocols
• Review consent process
for potential participants
• Administer therapy
• Evaluate adverse events
![Page 35: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/35.jpg)
Knowledgeable Administrative & Billing Personnel
“Medicare does not cover the patient care costs of clinical trials.”
Response: • June 7, 2000 – President Clinton issued an
executive memorandum directing the Medicare program to reimburse providers for the cost of routine patient care in clinical trials.
![Page 36: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/36.jpg)
Knowledgeable Billing Personnel
“Health insurance will not cover the costs of a
clinical trial.”
Response:• Many insurers and states cover the normal costs of
treatment on cancer clinical trials. Check with your doctor or insurance plan to see if you are covered.
![Page 37: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/37.jpg)
Knowledgeable Lab
• Experienced in filling and packing kits
• IATA shipping trained
• CLIA and COLA certification
• Trusted track record in ancillary participation
![Page 38: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/38.jpg)
Knowledgeable Radiation
• Updating and training to the newest technologies
• Offers wider clinical trial participation• Conventional vs IMRT or IGRT
![Page 39: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/39.jpg)
Willing Participants
• Opportunity to receive the next break- through drug
• Meet a personal milestone (i.e., graduation, wedding, anniversary)
• Altruistic
![Page 40: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/40.jpg)
Accrual Summary
January 1, 2008 through June 30, 2008
• 11.5% of all new patients were put on clinical trials
![Page 41: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/41.jpg)
Accrual Summary
January 1, 2008 through June 30, 2008
• 13.8% of new patients when excluding patients that had disease for which we did not have a trial or otherwise exclusionary diseases
(i.e. iron deficiency anemia, multiple sclerosis, Factor V patients, etc.)
![Page 42: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/42.jpg)
Accrual Summary• Add established patients with
progressive disease
• Add participants that are not seen by our physicians for prevention and cancer control
• > 15% of the potential participants are placed on clinical trials
![Page 43: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/43.jpg)
Belief in Research
• Enthusiastic participation by physician-investigators and administrators supporting a research project fosters the treatment environment necessary to create and promote clinical trials to the participant population.
![Page 44: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/44.jpg)
![Page 45: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/45.jpg)
Helpful Resources
• www.ecog.org
• ncctg.mayo.edu
• www.nylencancercenter.com
• www.clinicaltrials.gov
• www.cancer.gov
• www.irb-irc.net/
![Page 46: Advocating for Clinical Trial Accrual Karen Van De Steeg Executive Director.](https://reader035.fdocuments.us/reader035/viewer/2022062518/56649e2d5503460f94b1d3c0/html5/thumbnails/46.jpg)
Thank you